Richmond, VA Clinical Trials Report — April 2026

For Richmond residents considering participation in clinical research, April 2026 presents a critical window for those looking to join studies before enrollment concludes. Across the city, 41 clinical trials are slated to close within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 3 of these rapidly closing studies are still actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly.

Upcoming Deadlines for Clinical Trials

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various conditions, from kidney complications to certain cancers, are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Kidney transplant; complications (2 trials)
• Advanced lung non-small cell carcinoma (1 trial)
• Biofilm (1 trial)
• Anatomic stage III breast cancer AJCC V8 (1 trial)
• Atrial fibrillation (1 trial)
• Attention-deficit/hyperactivity disorder (1 trial)
• Anatomic stage II breast cancer AJCC V8 (1 trial)
• BK virus infection (1 trial)
• Brain injuries, traumatic (1 trial)
• Celiac disease (1 trial)

New Research Opportunities in Richmond

Richmond saw the opening of 4 new clinical trials this month, an increase from the 2 trials that launched in March 2026. This growth signifies ongoing opportunities for participation in cutting-edge medical research right here in the city. These new studies cover a range of conditions and include significant contributions from major sponsors.

• Novo Nordisk A/S is sponsoring NCT07533175, "AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight." This Phase 3 study, aiming for 630 participants, seeks to determine if NNC0487-0111 is safe and effective for individuals with excess body weight and type 2 diabetes. The treatment involves once-weekly injections under the skin.
• The VA Office of Research and Development is leading NCT07528690, "Microbiota trAnSplant ThERaPy In hEpatiC Encephalopathy (MASTERPIECE)." This Phase 2 trial, designed for 162 participants, aims to investigate whether altering gut microbes in Veterans with cirrhosis and hepatic encephalopathy can prevent future episodes of this brain-affecting condition using capsules derived from healthy individuals.
• Eli Lilly and Company is initiating NCT07533019, "A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo." This Phase 2 study, targeting 60 participants, will evaluate the tolerability and side effects of LY4005130 compared to a placebo in adults with non-segmental vitiligo (NSV), administered intravenously.

New trials this month are exploring conditions such as cirrhosis, diabetes mellitus, hepatic encephalopathy, non-segmental vitiligo (NSV), obesity, overweight, and vitiligo. The majority of these new studies are drug trials, with 3 new drug trials and 1 biological trial opening their doors.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are valuable opportunities to contribute to medical science. One of the 4 new trials launched this month is actively seeking healthy volunteers. Overall, Richmond currently has 37 clinical trials recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Eligibility for new trials this month primarily focuses on adults, with 4 studies specifically including older adults. No new trials are exclusively for children, females, or males.

Richmond's Leading Research Facilities

Richmond is home to a robust network of research institutions that consistently conduct a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Virginia Commonwealth University (153 trials)
• VCU Massey Comprehensive Cancer Center (117 trials)
• VCU Massey Cancer Center at Stony Point (60 trials)
• Bon Secours Saint Mary's Hospital (26 trials)
• Virginia Cancer Institute (25 trials)
• Bon Secours Cancer Institute at Reynolds Crossing (24 trials)
• Research Site (22 trials)
• Bon Secours Richmond Community Hospital (14 trials)
• VCU Medical Center (12 trials)
• Virginia Commonwealth University/Massey Cancer Center (12 trials)
• Virginia Commonwealth University Massey Cancer Center (11 trials)
• Virginia Commonwealth University Medical Center (10 trials)

The Virginia Commonwealth University system, including its Massey Comprehensive Cancer Centers, stands out as the primary hub for clinical research in Richmond, particularly in oncology. Bon Secours hospitals also play a significant role, offering diverse research opportunities across their facilities.

Expanding Your Search: Nearby Virginia Cities

While Richmond offers a substantial number of clinical trial opportunities, with 610 trials currently recruiting across 219 facilities, individuals may also find options in other communities within Virginia. Cities with active trials include Fairfax (7 trials), Charlottesville (7 trials), Blacksburg (2 trials), Lynchburg (1 trial), Midlothian (1 trial), Newport News (1 trial), Roanoke (1 trial), and Salem (1 trial). This highlights Richmond's position as a central research hub compared to other cities in the state.

As we move further into spring, Richmond's research community continues to drive medical innovation, offering diverse opportunities for patients and healthy volunteers to contribute to advancements in healthcare.